Showing results (461-470 of 668) with videos related to
Sort By:
Pageof 67
Hemasphere|May 8, 2024
The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myelomaAnna de Daniel, Luis Gerardo Rodríguez-Lobato, Natalia Tovar, et al.Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.Hemasphere|June 17, 2026
Mutational dynamics in patients with del(5q) MDS treated with lenalidomide prior to transfusion dependency-Molecular results from the Sintrarev clinical trialSofía Toribio Castelló, Felix López-Cadenas, Claude Preudhomme, et al.Hemasphere|September 1, 2022
Clonal Hematopoiesis and Epigenetic Age Acceleration in Elderly Danish TwinsMette Soerensen, Morten Tulstrup, Jakob Werner Hansen, et al.Hemasphere|June 24, 2026
Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphomaJulia C Kuehn, Lauritz Miarka, Roman Sankowski, et al.Hemasphere|July 2, 2026
Multiple myeloma: A tale of deregulated transcription factorsNahia Gómez-Echarte, Edurne San José-Enériz, Estíbaliz Urizar-Compains, et al.Hemasphere|July 9, 2026
Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemiaCharles C Chu, Clare B Heffernan, Nydia C Jaimes-Delgadillo, et al.Hemasphere|July 3, 2026
Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myelomaBruno Paiva, Irene Manrique, Ethan Thompson, et al.Hemasphere|July 23, 2026
Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenograftsChristopher M Smith, Ben Watts, Kathryn Evans, et al.Pageof 67